Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes
- PMID: 16353212
- DOI: 10.1002/cncr.21637
Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes
Abstract
Background: The primary aim of the current study was to determine whether radiographic tumor response is associated with patient-reported outcomes such as symptom response or health-related quality of life.
Methods: A metaanalysis was conducted of 21 available studies from 1995-2003 that provided data sufficient for examining the association between tumor response and patient-reported outcomes, including symptom response and health-related quality of life. A second aim was to examine the influence of possible moderating study variables on effect size variation.
Results: As hypothesized, patient-reported outcome improvement rates were most frequently associated with patients classified as a complete or partial response (CR/PR), followed by those with stable disease (SD) and progressive disease (PD). Moderate effect sizes were observed between the CR/PR and SD (effect size of 0.35) and CR/PR and PD categories (effect size of 0.43). A weak effect size was found between SD and PD (effect size of 0.16), raising concern over the meaningfulness of the SD category. No significant correlations were found between effect size and patient or study characteristics. Significant associations existed between treatment duration and age, study duration, survival, and symptom response rates, especially among PD patients.
Conclusion: Despite significant study-to-study heterogeneity, an important association exists in the correlation between tumor response and formal measures of change in patient-reported outcomes. A better understanding of this relation would be enhanced if future reports included estimates of effect size in patient-reported outcome change by tumor response category. Practical implications, limitations, and directions for future research are provided.
Copyright (c) 2005 American Cancer Society.
Similar articles
-
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2010 May;117(2):324-9. doi: 10.1016/j.ygyno.2010.01.040. Epub 2010 Feb 24. Gynecol Oncol. 2010. PMID: 20185168
-
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.Eur J Cancer. 2012 Feb;48(3):311-23. doi: 10.1016/j.ejca.2011.05.017. Eur J Cancer. 2012. PMID: 21689927 Clinical Trial.
-
[Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].Rofo. 2007 Nov;179(11):1174-80. doi: 10.1055/s-2007-963418. Epub 2007 Sep 5. Rofo. 2007. PMID: 17805998 German.
-
Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.Control Clin Trials. 2004 Dec;25(6):535-52. doi: 10.1016/j.cct.2004.09.003. Control Clin Trials. 2004. PMID: 15588741 Review.
-
Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.J Natl Cancer Inst Monogr. 2004;(33):78-101. doi: 10.1093/jncimonographs/lgh016. J Natl Cancer Inst Monogr. 2004. PMID: 15504921 Review.
Cited by
-
Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study.JMIR Cancer. 2024 Jun 5;10:e45331. doi: 10.2196/45331. JMIR Cancer. 2024. PMID: 38838304 Free PMC article.
-
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.Oncologist. 2011;16(5):632-40. doi: 10.1634/theoncologist.2010-0299. Epub 2011 Apr 1. Oncologist. 2011. PMID: 21459902 Free PMC article. Clinical Trial.
-
Patient-Reported Outcomes in Cancer Patients with HIV.Cancers (Basel). 2022 Nov 29;14(23):5889. doi: 10.3390/cancers14235889. Cancers (Basel). 2022. PMID: 36497369 Free PMC article.
-
Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.BMC Cancer. 2010 Dec 14;10:681. doi: 10.1186/1471-2407-10-681. BMC Cancer. 2010. PMID: 21156055 Free PMC article.
-
Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index.Health Qual Life Outcomes. 2007 Jun 14;5:34. doi: 10.1186/1477-7525-5-34. Health Qual Life Outcomes. 2007. PMID: 17570854 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials